Achaogen explicating the prospects of c-scape – achaogen (nasdaq akao) seeking alpha gas meter car


Of note, we wish to briefly go over the company for those who are new to this investment. Accordingly, Achaogen is operating out of San Francisco, CA, and is focusing on the innovation and commercialization of medicines to treat resistant bacterial infections. The company prides itself on creating a work community that is scientifically driven, supportive, and collaborative. That corporate culture then translates into an organization that is brewing a highly promising therapeutic pipeline of the next-generation antibiotics to potentially serve countless patients (as shown in figure 2).

While there are tremendous prospects in plazomicin, Achaogen is concurrently developing another promising molecule (C-Scape) to curb the increasingly alarming antibiotic resistance (as depicted in figure 3). C-Scape is a patient convenient and highly intelligent combination of ceftibuten (an approved 3rd-generation cephalosporin) and clavulanate (a highly efficacious beta-lactamase inhibitor). With excellent design, the clavulanate component neutralizes the bacterial enzyme (beta-lactamase) that, in and of itself, helps bacteria to become drug-resistant. Needless to say, both separate drugs have years of data supporting their efficacy and safety.

As an oral antibiotic, C-Scape is most likely the silver bullet for patients suffering from cUTI (whose bacteria are already resistant against the standard of care, the oral antibiotic amoxicillin). These bugs include the extended-spectrum beta-lactamase (“ESBL”)-producing E-coli and Klebsiella. Notably, the standard of care places an oral antibiotic for UTI to be the first-line treatment. That being said, the increasing resistance to oral drugs is quite concerning. Given that IV antibiotics are the last treatment resort for this infection, the demand for efficacious oral meds (to preserve and protect the last line, IV-treatment) is quite robust.

Despite that the data for C-Scape came from early studies, both the clinical and non-clinical findings were highly promising. It was found in vitro (test tubes) investigations that C-Scape has the potent activity against ESBL-producing Enterobacteriaceae and rapid bacterial killing (bactericidal) property in time-kill experiments. As alluded, the strong preclinical outcomes prompted Achaogen to initiate the phase 1 clinical study in 2017. Thereafter, the human trial commenced early this year.

Per figure 4, C-Scape has superb efficacy and safety across all doses, thereby indicating excellent benefits to risks profile. Notably, Achaogen intends on conducting additional development (including a phase 1 clinical pharmacology study to gauge the likelihood of clinical and commercial success). Thus far, the early data in combinations with the pharmacokinetic models based on the science of beta-lactam/beta-lactamase inhibitor suggests that the oral three times daily dosing is best.

It’s important for investors to be cognizant that Achaogen earned the BARDA contract back on September 2017. The prize entails $12M funding over the 9-month period (and the option to garner up to $18M in total). That aside, the FDA awarded C-Scape the Qualified Infectious Disease Product (“QIDP”) status for the treatment of cUTI, including acute pyelonephritis. The special designation allows C-Scape to have priority review and additional market exclusivity. Final Remarks

In all, the recent ADCOM disappointment for plazomicin is certainly temporary. The stock is already heading northbound toward the PDUFA set on June 25 – a binary event that has a favorable chance of catapulting the shares to a new high. The other highly likely scenario is that plazomicin will be prescribed off-label for BSI. As reflective of the stellar quality of its meds, the company recently won the CARB-X award for plazomicin and QIDP for C-Scape. Furthermore, C-Scape will highly likely post strong clinical outcomes (and to gain approval) to offer patients suffering from cUTI another outstanding treatment option. The key concern at this point in its growth cycle is that the stock is still “binary” in nature. In case if both cUTI and BSI fail to gain an approval on June 25, one can expect the shares to tumble over 80% and vice versa. Last but not least, we’d like to bid adieu by alerting investors to the presence of other innovators in the Specialty Report such as Melinta Therapeutics (NASDAQ: MLNT) and Paratek Pharmaceuticals (NASDAQ: PRTK).

Author’s Notes: We’re honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (“IBI”) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 322%, 138%, 205%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.